Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.

Abstract

PURPOSE CPX-1 is a novel, liposome-encapsulated formulation of irinotecan and floxuridine designed to prolong in vitro optimized synergistic molar ratios of both drugs postinfusion. This open-label, single-arm, dose-escalating phase I study was designed to determine the maximum tolerated dose and pharmacokinetics of CPX-1 in patients with advanced solid tumors. EXPERIMENTAL DESIGN Patients received CPX-1 at 30, 60, 100, 150, 210, or 270 units/m(2) (1 unit = 1 mg irinotecan + 0.36 mg floxuridine) infused over 90 minutes every 14 days in 28-day cycles. Pharmacokinetic samples were collected on days 1 and 15 of cycle 1. RESULTS Thirty-three patients were enrolled, treated, and evaluated for safety; 30 patients were evaluated for response. A 1:1 plasma irinotecan to floxuridine molar ratio was maintained for 8 to 12 hours. Grade 3/4 toxicities included diarrhea (24.2%), neutropenia (12.1%), and hypokalemia (12.1%); 1 patient (270 units/m(2)) died of persistent diarrhea, which led to dehydration and renal failure (grade 5). Partial response occurred in 3 (12%) of the 25 subjects evaluated through Response Evaluation Criteria in Solid Tumors. Progression-free survival lasting >6 months occurred in 9 patients, 6 with colorectal cancer. Among 15 colorectal cancer patients (10 with prior irinotecan), the calculated median progression-free survival was 5.4 months; 11 patients (72.7%) achieved disease control and 2 patients (13%) had partial response. CONCLUSIONS Outpatient CPX-1 was well tolerated and antitumor activity was shown in patients with advanced solid tumors. The recommended dose for future studies is 210 units/m(2). This is the first clinical evaluation of fixed drug ratio dosing designed to maintain synergistic molar ratios for enhanced therapeutic benefit.

DOI: 10.1158/1078-0432.CCR-08-0515

8 Figures and Tables

050200920102011201220132014201520162017
Citations per Year

267 Citations

Semantic Scholar estimates that this publication has 267 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Batist2009SafetyPA, title={Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.}, author={Gerald Batist and Karen Gelmon and Kim N. Chi and W. H. Miller and Stephen Chia and Lawrence D . Mayer and Christine E. Swenson and Andrew S. Janoff and Arthur C Louie}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2009}, volume={15 2}, pages={692-700} }